Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
BMRN
2 Reasons to Like BMRN and 1 to Stay Skeptical StockStory - Mon Nov 24, 10:00PM CST

2 Reasons to Like BMRN and 1 to Stay Skeptical

BMRN : 53.82 (-0.90%)
BMRN
Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks StockStory - Sun Nov 23, 9:33PM CST

Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks

BMRN : 53.82 (-0.90%)
ABBV
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know StockStory - Fri Nov 21, 5:51PM CST

AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know

ABT : 125.40 (+0.09%)
BMRN : 53.82 (-0.90%)
ABBV : 228.71 (-0.66%)
DXCM : 65.25 (+0.62%)
BIIB : 181.98 (+0.68%)
BMRN
BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings? StockStory - Thu Nov 20, 10:02PM CST

BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings?

BMRN : 53.82 (-0.90%)
BGS
1 Safe-and-Steady Stock on Our Watchlist and 2 We Question StockStory - Wed Nov 12, 10:41PM CST

1 Safe-and-Steady Stock on Our Watchlist and 2 We Question

SBGI : 14.65 (-3.36%)
BMRN : 53.82 (-0.90%)
BGS : 4.53 (-0.44%)
VTRS
Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know StockStory - Tue Nov 11, 2:55PM CST

Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know

OSCR : 17.18 (+0.47%)
VTRS : 10.76 (-0.74%)
BMRN : 53.82 (-0.90%)
BLCO : 16.81 (-0.88%)
QDEL : 27.82 (+1.05%)
BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England PR Newswire - Tue Nov 11, 8:00AM CST

SAN RAFAEL, Calif. , Nov. 11, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the Jefferies Global Healthcare Conference on Tuesday,...

BMRN : 53.82 (-0.90%)
CPNG
3 Cash-Producing Stocks with Promising Prospects StockStory - Sun Nov 9, 10:43PM CST

3 Cash-Producing Stocks with Promising Prospects

AXON : 550.61 (+1.30%)
BMRN : 53.82 (-0.90%)
CPNG : 27.02 (+1.73%)
BMRN
The 5 Most Interesting Analyst Questions From BioMarin Pharmaceutical’s Q3 Earnings Call StockStory - Sun Nov 2, 11:31PM CST

The 5 Most Interesting Analyst Questions From BioMarin Pharmaceutical’s Q3 Earnings Call

BMRN : 53.82 (-0.90%)
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria PR Newswire - Wed Oct 29, 8:00AM CDT

Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet alone

BMRN : 53.82 (-0.90%)

Barchart Exclusives

Is This Dividend Stock a Buy for 2026 After Rising 265% in 2025? Barchart - Thu Dec 4, 6:30PM CST
Anglogold Ashanti shares have soared this year amid a spike in gold prices. While the shares might take a breather for now, it is a buy-on-the-dip candidate for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot